Table 1.
Patient Characteristics and Treatment Outline
| Basic Characteristics | Estimate |
|---|---|
| Age in years, median (range) | 57 (39–67) |
| Male/female (n) | 9/2 |
| Preoperative KPS, median (range) | 90 (70–100) |
| MGMT methylation (n) | 4 |
| Tumor location (n) | |
| Frontal | 2 |
| Parietal | 2 |
| Temporal | 5 |
| Parieto-occipital | 2 |
| SR-surgery and TTFields | Median (range) |
| Skull defect area (cm2) | 10.5 (7–48) |
| Field intensity in the tumor (V/m) | 173 (111–210) |
| Relative field enhancement (%) | 32 (25–59) |
| Absolute field enhancement (V/m) | 40 (28–69) |
| TTFields compliance rate (%) | 90 (48–98) |
| TTFields duration (months) | 7.6 (2.3–24.0) |
| Extent of resection | N |
| No residual tumor | 4 |
| Nonmeasurable residual tumor | 5 |
| Measurable residual tumor | 2 |
| Medical treatment | Estimate |
| Bevacizumab monotherapy (n) | 8 |
| Bevacizumab/irinotecan (n) | 1 |
| Temozolomide rechallenge (n) | 2 |
| Daily methylprednisolone dose in mg, median (range) | 14.3 (0–50) |